GlassScriptPhysician profile
Gabriella G Basdekis
NPI 1215709878
$3,428.69
in general payments reported to CMS, 2019-2025
21 companies · $2,154 in 2025
The $2,154 reported for 2025 was more than what 92% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,275 · 2025: $2,154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,398 · Education: $31.07.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,397.62 |
| Education | $31.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $997.24 | 2024-2025 | |
| Janssen Biotech, INC. | $494.98 | 2024-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $229.98 | 2024-2025 | Entyvio, Eohilia |
| Madrigal Pharmaceuticals | $229.65 | 2024-2025 | Rezdiffra, Resmetirom |
| Intercept Pharmaceuticals, INC. | $182.10 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $171.87 | 2024-2025 | Voquezna |
| Gilead Sciences, INC. | $129.33 | 2024-2025 | |
| Lilly USA, LLC | $121.59 | 2024-2025 | Omvoh |
| Boston Scientific Corporation | $121.43 | 2025 | Axonics |
| Qol Medical, LLC | $106.02 | 2024-2025 | Sucraid, Sucraid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $105.96 | 2024-2025 | Xifaxan, Trulance |
| Ardelyx, INC. | $96.38 | 2024-2025 | Ibsrela |
| Ipsen Biopharmaceuticals, INC | $83.82 | 2024-2025 | Iqirvo |
| Celltrion USA INC. | $78.29 | 2024-2025 | Vegzelma, Zymfentra |
| Regeneron Healthcare Solutions, INC. | $70.72 | 2024-2025 | Dupixent |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $65.16 | 2024-2025 | Vowst, Zenpep |
| Merck Sharp & Dohme LLC | $48.15 | 2024 | Dificid |
| Pfizer INC. | $46.99 | 2025 | |
| Daiichi Sankyo INC. | $18.58 | 2024 | Injectafer |
| Orphalan INC | $16.31 | 2025 | Cuvrior |
| Genzyme Corporation | $14.14 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gabriella Basdekis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.